AUTHOR=Yeung Andy Wai Kan , Atanasov Atanas G. , Sheridan Helen , Klager Elisabeth , Eibensteiner Fabian , Völkl-Kernsock Sabine , Kletecka-Pulker Maria , Willschke Harald , Schaden Eva 

TITLE=Open Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 11 - 2020

YEAR=2021

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.587526

DOI=10.3389/fphar.2020.587526

ISSN=1663-9812

ABSTRACT=Open innovation in medical and pharmaceutical research has grown steadily over
the last decade. However, the performance of the published literature in terms of
scientific impact and gain of social media attention remained largely unexplored.
The scientific literature of open innovation was examined by means of
bibliometric analyses to identify the most prolific authors, organizations,
countries, journals, research areas, and recurring terms. By accessing Web of
Science Core Collection and Altmetric electronic databases, citation-related and
Altmetric data were evaluated. Public-private partnerships and a selection of
newly introduced potential novel drugs introduced in the analyzed publications
were identified. North America and Europe were the major literature contributors.
Research outputs were mainly published in journals focused on business and
economics, pharmacology and pharmacy, and engineering. Many pharmaceutical
and biotechnological companies contributed to the analyzed publications, with
higher mean citation counts and social media attention (Altmetric score) than
non-industry papers. Public-private partnerships fostered financial support,
sharing of expertise and intellectual property and research collaborations. In
summary, open innovation might serve as a powerful strategy to both benefit the
involved industry entities as well as to accelerate the development of solutions
and products for the betterment of human health.